Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared with rates in the clinical trials of another vaccine and may not reflect the rates observed in practice.
A total of 4,013 children were vaccinated with a single dose of KINRIX in 4 clinical trials. Of these, 381 children received a non-U.S. formulation of KINRIX (containing ≤2.5 mg 2‑phenoxyethanol per dose as preservative).
The primary study (Study 048), conducted in the United States, was a randomized, controlled clinical trial in which children aged 4 to 6 years were vaccinated with KINRIX (n = 3,156) or control vaccines (INFANRIX and IPOL vaccine [IPV, Sanofi Pasteur SA]; n = 1,053) as a fifth DTaP vaccine dose following 4 doses of INFANRIX and as a fourth IPV dose following 3 doses of IPOL. Participants also received the second dose of U.S.‑licensed measles, mumps, and rubella (MMR) vaccine (Merck & Co., Inc.) administered concomitantly, at separate sites.
Data on adverse events were collected by parents/guardians using standardized forms for 4 consecutive days following vaccination with KINRIX or control vaccines (i.e., day of vaccination and the next 3 days). The reported frequencies of solicited local reactions and general adverse reactions in Study 048 are presented in Table 1.
In 3 studies (Studies 046, 047, and 048), children were monitored for unsolicited adverse events, including serious adverse events that occurred in the 31‑day period following vaccination, and in 2 studies (Studies 047 and 048), parents/guardians were actively queried about changes in the child’s health status, including the occurrence of serious adverse events, through 6 months postvaccination.
Table 1. Percentage of Children Aged 4 to 6 Years Reporting Solicited Local or General Adverse Reactions within 4 Days of Vaccinationa with KINRIX or Separate Concomitant Administration of INFANRIX and IPV when Coadministered with MMR Vaccine (Study 048) (Total Vaccinated Cohort)IPV = Inactivated poliovirus vaccine (Sanofi Pasteur SA); MMR = Measles, mumps, and rubella vaccine (Merck & Co., Inc.). Total Vaccinated Cohort = All vaccinated participants for whom safety data were available. n = Number of children with evaluable data for the reactions listed. a Within 4 days of vaccination defined as day of vaccination and the next 3 days. b Local reactions at the injection site for KINRIX or INFANRIX. c Statistically higher than comparator group (P <0.05). d Grade 2 defined as painful when the limb was moved; Grade 3 defined as preventing normal daily activities. e Grade 3 defined as preventing normal daily activities. f Grade 3 defined as not eating at all. |
Adverse Reaction | KINRIX | INFANRIX + IPV |
Localb | n = 3,121-3,128 | n = 1,039-1,043 |
Pain, any | 57c | 53 |
Pain, Grade 2 or 3d | 14 | 12 |
Pain, Grade 3d | 2c | 1 |
Redness, any | 37 | 37 |
Redness, ≥50 mm | 18 | 20 |
Redness, ≥110 mm | 3 | 4 |
Arm circumference increase, any | 36 | 38 |
Arm circumference increase, >20 mm | 7 | 7 |
Arm circumference increase, >30 mm | 2 | 3 |
Swelling, any | 26 | 27 |
Swelling, ≥50 mm | 10 | 12 |
Swelling, ≥110 mm | 1 | 2 |
General | n = 3,037-3,120 | n = 993-1,036 |
Drowsiness, any | 19 | 18 |
Drowsiness, Grade 3e | 1 | 1 |
Fever, ≥99.5°F | 16 | 15 |
Fever, >100.4°F | 7c | 4 |
Fever, >102.2°F | 1 | 1 |
Fever, >104°F | 0 | 0 |
Loss of appetite, any | 16 | 16 |
Loss of appetite, Grade 3f | 1 | 1 |
In Study 048, KINRIX was non-inferior to INFANRIX with regard to swelling that involved >50% of the injected upper arm length and that was associated with a >30 mm increase in mid-upper arm circumference within 4 days following vaccination (upper limit of 2-sided 95% Confidence Interval for difference in percentage of KINRIX [0.6%, n = 20] minus INFANRIX [1.0%, n = 11] ≤2%).
Serious Adverse Events
Within the 31‑day period following study vaccination in 3 studies (Studies 046, 047, and 048) in which all participants received concomitant MMR vaccine (U.S.‑licensed MMR vaccine [Merck & Co., Inc.] in Studies 047 and 048, non—U.S.‑licensed MMR vaccine in Study 046), 3 participants (0.1% [3/3,537]) who received KINRIX reported serious adverse events (dehydration and hypernatremia; cerebrovascular accident; dehydration and gastroenteritis) and 4 participants (0.3% [4/1,434]) who received INFANRIX and inactivated poliovirus vaccine (Sanofi Pasteur SA) reported serious adverse events (cellulitis, constipation, foreign body trauma, fever without identified etiology).